Core Viewpoint - Fangzhou Inc. reported a profitable first half of 2025, driven by an expanding user base, improved operating efficiency, and accelerated AI deployment in healthcare services and internal operations [1] Financial Performance - Revenue for the first half of 2025 reached RMB 1.494 billion, marking a 12.9% increase year-on-year [2] - Net profit was RMB 12.5 million, a significant turnaround from a loss of RMB 818.7 million in the same period last year [2] - Adjusted net profit increased by 16.8% to RMB 17.6 million, achieving a new high [2] User Growth - Registered users on the platform grew by 15.8% year-on-year to 52.8 million [3] - Monthly active users surged by 34.4% to 11.9 million [3] - The number of registered doctors increased to 229,000, with a paid user repurchase rate of 85.4%, indicating strong user retention [3] Revenue Breakdown - Revenue from online retail pharmacy services rose by 28.2% to RMB 864 million [4] - Revenue from medical services increased by 11.4% to RMB 357 million [4] - The drug catalog expanded to 215,000 SKUs, with prescription medicines making up approximately 62% [4] Product Innovation - The company launched several innovative drugs through its platform from leading pharmaceutical companies, including Novo Nordisk and Novartis AG [5] AI Integration - Fangzhou accelerated the implementation of AI across various functions, enhancing user services, procurement, marketing, and content production [6] - The upgraded "AI+H2H" platform supports immediate health consultations and long-term disease management, with AI tools assisting doctors and patients [7] - Internally, AI tools were deployed for procurement and content creation, improving operational efficiency [8] Strategic Expansion - The company is enhancing integration with China's national medical insurance system, improving service capabilities for insured patients [9] - Future plans include a "technology innovation + digital integration" strategy, focusing on deeper AI integration and collaboration with drugmakers and health institutions [10] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [11]
Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand